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Introduction: Liver X receptors are established sensors of lipid and cholesterol homeostasis. Recent studies have
reported that these receptors are involved in the regulation of inflammation and immune responses. We attempted
to identify single nucleotide polymorphisms (SNPs) of the NR1H3 gene associated with the susceptibility to systemic
lupus erythematosus (SLE).
Methods: SNPs were genotyped using SNaPSHOT assay in 300 Korean patients with SLE and 217 normal controls
(NC), and in replication samples (160 SLE patients and 143 NC). Also, the functional effects of NR1H3 gene promoter
polymorphisms were analyzed using a luciferase assay, real-time polymerase chain reaction, B cell proliferation assay
and an electrophoretic mobility shift assay.
Results: We identified five polymorphisms: −1851 T > C (rs3758673), −1830 T > C (rs3758674), −1003 G > A
(new), −840 C > A (rs61896015) and −115 G > A (rs12221497). There was a significant and reproducible
difference in the −1830 T > C, −1003 G > A and −115 G > A polymorphisms between the SLE and the NC.
Luciferase activity of the structure containing −1830 C was less enhanced compared to the structure
containing −1830 T in basal, GW3965 and T0901317 treated Hep3B cells (P = 0.009, P = 0.034 and P <0.001,
respectively). Proliferation of the −1830 TC type was increased compared to the −1830 TT type in basal,
GW3965 and T0901317 treated B cells from SLE patients (P = 0.011, P = 0.040 and P = 0.017, respectively).
Transcription factor GATA-3 preferentially bound the −1830 T allele in the promoter.
Conclusions: NR1H3 genetic polymorphisms may be associated with disease susceptibility and clinical
manifestations of SLE. Specifically, −1830 T > C polymorphism within NR1H3 promoter region may be involved
in regulation of NR1H3 expression.Introduction
Systemic lupus erythematosus (SLE) is an autoimmune
disease characterized by dysregulation of the immune sys-
tem involving the hyperactivity of T and B cells, elevated
production of pathogenic autoantibodies, complement
activation, and the formation of immune complexes caus-
ing multiorgan damage by deposition in host tissue [1].
Although the exact pathogenesis of SLE remains elusive,
extremely complicated and multifactorial interactions bet-
ween genetic and environmental factors are thought to* Correspondence: chsuh@ajou.ac.kr
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stated.contribute to the development of the disease [2]. Genetic
variation of various genes may lead to different inflam-
mation, immune responses and susceptibility to SLE [3].
Several genetic association studies have been performed in
patients with SLE and various genes encoding proteins
with regulatory or adaptive functions in the immune
system have been considered as candidates [4,5]. Well-
established risk factors include alleles in the major his-
tocompatibility complex, interferon regulatory factor 5,
integrin alpha M, signal transducer and activator of tran-
scription 4 and B lymphoid tyrosine kinase in genome-
wide association studies in SLE [6,7]. Many susceptibility
genes fall into key pathways that are consistent with
previous studies implicating immune complexes, hostd. This is an Open Access article distributed under the terms of the Creative
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the pathogenesis of SLE [6,8].
Liver X receptor (LXR) alpha (NR1H3) and beta
(NR1H2) can influence macrophage biology by modula-
tion of lipid metabolism and by effects on innate immu-
nity. The release of cytokines including interleukin (IL)-1,
IL-6 and tumor necrosis factor-α from macrophages re-
sults in recruitment of monocytes and cross-talk with
T cells, perpetuates cellular activation and further pro-
motes atherosclerotic lesion development [9]. The anti-
inflammatory effect of LXRs was first described in a
study that demonstrated that LXR activation attenuated
Escherichia coli- or lipopolysaccharide (LPS)-induced ex-
pression of pro-inflammatory molecules including IL-6,
inflammatory nitric oxide synthase and cyclooxygenase-2
in macrophages from wild type mice, but not LXR null
mice [10]. LXR is reportedly essential for macrophage
survival and clearance of invading bacteria in protective
immune responses [10,11], whereas LXR activation also
inhibits lymphocyte proliferation [12]. A recent study
found that LXRs mediate the regulation of Th17 cell dif-
ferentiation and autoimmunity [13]. However, the possible
association between LXRs genetic polymorphisms and
SLE has not been addressed.
In this study, we attempted to identify polymorphisms
of the NR1H3 and NR1H2 genes associated with suscep-
tibility to SLE in Koreans and to elucidate the functional
effect of these polymorphisms.
Methods
Study subjects
Three hundred SLE patients and 217 normal controls
(NC) were enrolled from Ajou University Hospital in
Suwon, Korea. All patients satisfied at least four of the
1982 revised American College of Rheumatology (ACR)
criteria for SLE [14]. The patients’ medical histories were
reviewed from the onset of disease until admission to the
study. Clinical features of the disease, as defined by ACR
criteria, were recorded in standardized questionnaires. In-
formation about the medical history, clinical symptoms
and physical examination were registered by a rheuma-
tologist in a database when blood sampling was done. For
each patient, blood cell count, routine chemistry, uri-
nalysis, C-reactive protein and anti-dsDNA antibody were
examined. Anti-dsDNA antibody was measured by radio-
immunoassay using a commercial kit (Trinity Biotech,
Bray, Ireland). Clinical manifestations including oral ulcer,
arthritis, serositis, rash, nephritis, leukopenia (<4 × 103
cells/μL), lymphopenia (<1 × 103 cells/μL) and throm-
bocytopenia (<100 × 103 cells/μL), anti-dsDNA antibody
(>7.0 IU/ml) and anti-cardiolipin antibody (either or both
immunoglobulin G (IgG) >20 GPL-U/mL and IgM posi-
tive >20 MPL-U/mL) were defined by positive involve-
ment when it was positive at least once during the diseaseduration. The NCs were chosen from the general popula-
tion using a screening questionnaire, which had to indi-
cate no history of rheumatic diseases or autoimmune
disorders. Also, replication samples were collected from
other SLE patients (n = 160) and NC (n = 143). All the
subjects who participated in this study were ethnically
Korean. The study was approved by the Institutional
Review Board of Ajou University Hospital and all subjects
gave their informed consent.
Identification and genotyping of SNPs
Fifty SLE patients and 50 NC Korean volunteers were
used for SNP identification. Genomic DNA was extracted
from whole blood using the QuickGene DNA whole blood
kit S (Fujifilm Life Science, Tokyo, Japan). The NR1H3
gene located between the promoter region and intron 2
region was amplified by polymerase chain reaction (PCR)
with Amfisure PCR Master Mix (GenDEPOT, Barker, TX,
USA). The NR1H2 gene located in the promoter region
and between the exon 10 region and the 3’ untranslated
region were amplified by PCR. We identified possible
polymorphisms in the NR1H3 and NR1H2 genes that were
screened by direct sequencing (Bionics, Seoul, Korea). A
minor allele frequency ≥5% was considered to indicate a
SNP. Additionally, SNP genotyping was performed using
the SNaPSHOT ddNTP primer extension kit (Applied
Biosystems, Foster City, CA, USA) for SLE patients
(n = 250) and NC (n = 167) and replication samples (160
SLE patients and 143 NC).
Preparation of promoter constructs
Six reporter structures composed of the NR1H3 -1830
T >C, −1003 G >A and −115 G >A sequence carrying
each allele and the luciferase reporter gene were transfected
into the Hep3B cell line. A 500 bp-sized fragment
(from −2121 to −1622) of the NR1H3 gene was PCR-
amplified using either −1830 T homozygous or −1830 C
homozygous genomic DNA as a template and the following
primers: forward primer: 5′- CGGCGGGGTACCACATCT
ATGCCAGCCCTGTTTCAG −3′; the bold characters
represent the KpnI site, reverse primer: 5′- CCGC
CGCTCGAGACTGAGCCCCAGCGGCTTTC −3′; the
bold characters denote the XhoI site. A 500 bp-sized frag-
ment (from −1266 to −767) of the NR1H3 gene was PCR
amplified using either −1003 G homozygous or −1003 A
homozygous genomic DNA as a template and the follo-
wing primers: forward primer: 5′- CTATCGATAGG
TACCCTCCCCTCAGCCTTTCCCCA −3′; reverse
primer: 5′- ATCGCAGATCTCGAGTCCCCCTCACTC
CAACACTGAG −3′. A 500 bp-sized fragment (from −374
to +126) of the NR1H3 gene was PCR amplified using
either −115 G homozygous or −115 A homozygous
genomic DNA as a template and the following primers:
forward primer: 5′- CTATCGATAGGTACCGTTTTG
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ATCGCAGATCTCGAGCAGGTAATGAAGGAGGCT
GA −3′. Each PCR product was subcloned separately
into the KpnI–XhoI site of the pGL3-Basic luciferase re-
porter vector (Promega, Madison, WI, USA).
Transfection and luciferase reporter assays
Hep3B cells (hepatocellular carcinoma cell line #58064;
Korean Cell Line Bank (KCLB), Seoul, Korea) were cul-
tured in Roswell Park Memorial Institute (RPMI) 1640
(Invitrogen, Carlsbad, CA, USA) and COS-7 cells (African
Green Monkey kidney cell line #21651, KCLB) were cul-
tured in high-glucose (D)MEM (Hyclone, Logan, UT,
USA) supplemented with 10% heat-inactivated fetal bo-
vine serum (FBS) at 37°C in a 5% CO2 incubator. Hep3B
and COS-7 cells were transfected by using FuGENE6
(Roche, Mannheim, Germany) according to the manufac-
turer’s instructions. Reporter plasmid DNA of NR1H3 0.5
μg and pSV-β-galactosidase plasmid DNA (Promega) 0.5
μg were resuspended and further gently mixed with 1.5 μL
of FuGENE6 reagents described previously [15]. The
relative transcriptional activity of each construct was
expressed as the ratio of luciferase activity to β-galactosi-
dase activity using a luminometer, the LUMIstar OPTIMA
(BMG LABTECH, Ortenberg, Germany). The transfections
and luciferase assays were conducted in triplicate, and the
experiments were repeated at least three times with
different cell preparations as described previously [15].
Pharmacological treatment and reporter gene assay
Hep3B and COS-7 cells were transfected with NR1H3
promoter pGL3-basic constructs using FuGENE6
(Promega) according to the manufacturer’s instructions.
After incubation for six hours, the medium was replen-
ished with 500 μL of fresh medium with 20% FBS, and
the cells were incubated a further 18 hours at 37°C in a
5% CO2 incubator. Twenty four hours after transfec-
tion, cells were treated with either 200 ng/mL LPS
(Sigma-Aldrich, St. Louis, MO, USA), 3 μmol/L 3-[3-
[N-(2-chloro-3-trifluoro methylbenzyl)-(2,2-dipheny-
lethyl)amino]propyloxy]phenylacetic acid hydrochloride
(hydrochloride GW3965; GW3965, Sigma-Aldrich) or
5 μmol/L N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-
1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesul-
fonamide (sulfonamide T0901317; T0901317, Cayman,
Ann Arbor, MI, USA) for 24 hours. These concentrations
and time were chosen based on previous work [16].
Primary culture and Epstein-Barr virus transformation of
lymphocytes
The peripheral blood mononuclear cells were separated
from peripheral blood using Histopaque (Sigma-Aldrich)
and counted to provide 1 × 106 cells/ml. Then, the
prepared Epstein-Barr virus (EBV; B95-8 cell line) wasadded. After 24 hours incubation in a CO2 incubator,
0.5 μg/ml cyclosporine A was added and the cells cultured
for three weeks. After one week, cell line formation was
confirmed. After two weeks, adequate transformation was
confirmed by phase microscopy (until medium begins to
turn orange/yellow and small clumps of cells become vis-
ible). The media change step was repeated until the total
cell number exceeded 5 × 106 cells/ml. Finally, the trans-
formed cells were retrieved and preserved at −80°C in a
deep freezer.
Total RNA extraction and quantitative real-time RT-PCR
The EBV-transformed B cell line was cultured in RPMI
1640 supplemented with 10% heat-inactivated FBS at 37°C
in a 5% CO2 incubator. Total RNA was extracted from B
cells using a RNA mini extraction kit (Inclone, Seoul,
Korea) according to the manufacturer’s suggested pro-
tocol. Total RNA (2 μg) was converted to cDNA by a
GoScript reverse transcription system kit (Promega) ac-
cording to the manufacturer’s suggested protocol. After
annealing at 25°C for five minutes, extension at 42°C for
one hour, inactive reverse transcriptase at 70°C for 15
minutes, the product was stored at −20°C until used.
The reverse transcription PCR (RT-PCR) reaction was
performed by PCR with amfisure PCR Master Mix (Gen-
DEPOT) under the following conditions: hot start at 94°C
for four minutes followed by 37 cycles of 95°C for one
minute, 58°C for one minute, and 72°C for thirty seconds
with a final extension at 72°C for ten minutes. NR1H3 was
amplified with the following primers: forward primer:
5′- AGGGCTGCAAGGGATTCTTCC −3′, reverse pri-
mer: 5′- TCTGACAGCACACACTCCTCCC −3′. Samples
were subjected to parallel amplification of the constitu-
tively expressed, housekeeping gene, human β-actin
using the following primers: forward primer: 5′-
TCCTTCTGCATCCTGTCGGC −3′, reverse primer: 5′-
CAAGAGATGGCCACGGCTGC −3′.
The real-time PCR reaction was performed by a
Rotor-Gene SYBR Green PCR kit (Qiagen, Valencia, CA,
USA) with the same primers of RT-PCR under the
following conditions: heating to 95°C for five minutes,
and 40 cycles of 95°C for five seconds, 58°C for ten
seconds, and 72°C for thirty seconds.
B cell proliferation assay
B cells were seeded into 96-well plates at a density of 1 ×
105 cells. After incubation for 24 hours, cells were treated
with either 200 ng/mL LPS (Sigma-Aldrich), 3 μmol/L
GW3965 (Sigma-Aldrich) or 5 μmol/L T0901317 (Cayman)
for 24 hours. The concentrations and time were chosen
based on previous data. After incubation for 24 hours, cell
viability was assessed using the CellTiter 96 AQueous One
Solution Cell Proliferation Assay (Promega). This is a colori-
metric assay containing a tetrazolium compound. When the
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product that is soluble in cell culture medium and is max-
imally absorbed at 490 nm. Assays were conducted in tripli-
cate, and the experiments were repeated at least three times.
Nuclear extract preparation and electrophoretic mobility
shift assay
Hep3B cells were washed with ice-cold phosphate-buffered
saline before being suspended in ice-cold hypoosmotic buf-
fer comprised of 10 mM HEPES/KOH (pH 7.9), 2 mM
MgCl2, 0.1 mM ethylenediaminetetraactic acid (EDTA),
10 mM KCl, 1 mM dithiothreitol (DTT), 1 mM phenyl-
methanesulfonylfluoride (PMSF), 1 mM NaVO3, 10 mM
NaF and complete protease inhibitor cocktail (Roche,
Basel, Switzerland). The cells were incubated on ice for
10 minutes and for an additional 15 minutes in the
presence of 0.2% Nonidet P-40. After centrifugation at
15,000 × g for 30 seconds, the pellet was resuspended in a
cold saline buffer that contained 50 Mm HEPES/KOH (pH
7.9), 50 mM KCl, 300 mM NaCl, 0.1 mM EDTA, 10% (v/v)
glycerol, 1 mM DTT, 1 mM PMSF and protease inhibitors.
The mixture was incubated on ice for 30 minutes. After
centrifugation at 15,000 × g for 30 minutes at 4°C, the
supernatant containing the nuclear proteins was stored at
−80°C until use. The following double-stranded oligonucle-
otides were used as probes for the electrophoretic mobility
shift assay (EMSA): for NR1H3 -1830 T >C 5′ - AG
ATTTCCTA[t/c]CAAAGGCTCT - 3′, CdxA as a nonspe-
cific competitor, 5′ - AGATCTGGTACCATTTAAGCCC
TCGAGATCTA - 3′ and for GATA-3 as a specific com-
petitor, 5′ - GTTATTTATCTCTTAGTTGTAGTTATTTA
TCTCTTGTTGTA - 3′. The double-stranded oligonucle-
otides were annealed by incubation at 95°C for five minutes
followed by gradual cooling to room temperature. The
double-stranded DNA probes were radiolabeled at their 5′-
ends with DNA polymerase I (Klenow fragment; Promega)
and [α-32P]CTP. The reaction mixtures (10 μl), which con-
tained 5 μg of nuclear extract, 10 mM HEPES (pH 7.9), 250
ng poly(dI:dC), 0.005 mM MgCl2, 75 mM NaCl, 5 mM
DTT, 1 mM NaNO3, 10 mM NaF, 1 mM EDTA, 400 ng
bovine serum albumin and 50% glycerol, were preincubated
on ice for 20 minutes, and then incubated for 20 minutes
on ice in the presence of 0.2 pmol of radiolabeled probe.
The reaction mixtures were then subjected to electro-
phoresis on a native 6% polyacrylamide gel. For com-
petition experiments, unlabeled blunt-ended competitor
oligonucleotides were added to the binding reaction mix-
tures before the addition of the radiolabeled oligonucleotide
probes. The gels were dried and radioactivity was detected
using a FLA3000 scanner (Fuji Photo Film, Tokyo, Japan).
Statistical analyses
The genotype frequency was tested for significant depar-
ture from Hardy-Weinberg equilibrium at each SNP bychi-square analysis. Differences in genotype frequency
between the cases and controls were tested by the chi-
square test and calculation of the odds ratio (OR) and the
95% confidence interval (CI). Three logistic regression
models (codominant, dominant and recessive) were used
to analyze the SNP after controlling for age and sex as co-
variates. Differences in the mean value of the phenotypic
characteristics between groups were compared by an ana-
lysis of variance (ANOVA) test and a t-test. P values <0.05
were considered to be significant. Haplotypes were ana-
lyzed using Haploview version 4.2 based on the EM algo-
rithm [17]. Linkage disequilibrium between loci was
measured using the absolute value of Lewontin’s /D′/ and
r2 [18]. Statistical analyses were conducted using the SPSS
version 12.0 software (SPSS, Chicago, IL, USA).
Results
Clinical characteristics of the study subjects
The mean age of the SLE patients was 30.6 ± 9.2 years and
89.0% were female. The mean age of the NC was 29.8 ±
5.8 years and 88.5% were female. Clinical features of SLE
patients are as follows with decreasing frequency: arthritis
(67.3%), oral ulcer (49.3%), rash (39.0%), nephritis (26.3%)
and serositis (13.3%). In replication samples, the mean age
of the SLE patients was 42.3 ± 13.4 years and 81.3% were
female. The mean age of the NC was 41.7 ± 9.7 years and
81.8% were female (Additional file 1).
Genotype and haplotype frequencies
The allele and genotype frequencies of the NR1H3 poly-
morphisms are presented in Table 1. Genotype distribu-
tions of all the polymorphisms satisfied the Hardy–
Weinberg proportions in the NC (P >0.05). Based on an
allele frequency ≥5%, five SNPs of the NR1H3 gene were
identified; −1851 T > C (rs3758673) and −1830 T > C
(rs3758674) in the promoter region, and −1003 G > A
(new), −840 C > A (rs61896015) and −115 G > A
(rs12221497) in the intron 1 region.
In the −1830 T > C polymorphism, the genotype fre-
quency of the minor allele was significantly higher in the
SLE patients when compared to the NC (P = 0.001 for
the co-dominant model, P = 0.002 for the recessive
model). Also, the minor allele of the −1003 G > A poly-
morphism was significantly more frequent in the SLE
patients than in the NC (P = 0.002 for the co-dominant
model, P = 0.002 for the recessive model). In addition,
the SLE patients had the minor allele of the −115 G > A
polymorphism more frequently (P = <0.001 for the co-
dominant model, P = 0.001 for the recessive model).
However, screening of the NR1H2 gene for genetic vari-
ation did not reveal differences between the SLE and the
NC (data not shown).
In the replication samples, the minor allele of the −1830
T > C and −115 G > A polymorphisms were significantly
Table 1 The genotype and allele frequencies of polymorphisms in the NR1H3 gene
Loci Genotype Our Replication Combine
SLE
(n = 300)
NC
(n = 217)
P value OR (95% CI) SLE
(n = 160)
NC
(n = 143)
P value OR (95% CI) SLE
(n = 460)
NC
(n = 360)
P value OR (95% CI)
−1851 T > C TT 172 (57.3%) 115 (53.0%) co : 0.281 1.171 (0.879 ~ 1.559) 93 (58.1%) 78 (54.5%) co : 0.578 1.107 (0.577 ~ 1.851) 265 (57.6%) 193 (53.6%) co : 0.215 1.151 (0.921 ~ 1.438)
TC 112 (37.3%) 57 (40.1%) do : 0.507 1.132 (0.786 ~ 1.630) 55 (34.4%) 53 (37.1%) do : 0.816 1.051 (0.689 ~ 1.603) 167 (36.3%) 140 (38.9%) do : 0.425 1.118 (0.723 ~ 2.163)
CC 16 (5.3%) 15 (6.9%) re : 0.316 1.094 (0.918 ~ 1.305) 12 (7.5%) 12 (8.4%) re : 0.557 1.071 (0.852 ~ 1.347) 28 (6.1%) 27 (7.5%) re : 0.252 1.085 (0.944 ~ 1.246)
q. 0.240 0.270 0.285 1.080 (0.938 ~ 1.245) 0.250 0.270 0.567 1.055 (0.878 ~ 1.267) 0.242 0.269 0.212 1.074 (0.960 ~ 1.201)
HWE 0.790 0.487 0.817
−1830 T > C TT 238 (79.3%) 195 (89.9%) co : 0.001 0.431 (0.260 ~ 0.714) 131 (81.9%) 129 (90.2%) co : 0.034 0.483 (0.246 ~ 0.948) 369 (80.2%) 324 (90.0%) co : <0.001 0.447 (0.299 ~ 0.668)
TC 58 (19.3%) 22 (10.1%) do : 0.999 0.000 (0.000 ~ NA) 28 (17.5%) 14 (9.8%) do : 1.000 0.000 (0.000 ~ NA) 86 (18.7%) 36 (10.0%) do : 0.999 0.000 (0.000 ~ NA)
CC 4 (1.3%) 0 (0.0%) re : 0.002 0.658 (0.507 ~ 0.855) 1 (0.6%) 0 (0.00%) re : 0.041 0.698 (0.495 ~ 0.985) 5 (1.1%) 0 (0.0%) re : <0.001 0.671 (0.546 ~ 0.826)
q. 0.110 0.051 0.001 0.658 (0.512 ~ 0.512) 0.090 0.050 0.038 0.706 (0.508 ~ 0.981) 0.104 0.05 <0.001 0.672 (0.552 ~ 0.820)
HWE 0.432 0.538 0.318
−1003G > A GG 250 (83.3%) 201 (92.6%) co : 0.002 0.396 (0.223 ~ 0.705) 139 (86.9%) 131 (91.6%) co : 0.194 0.606 (0.285 ~ 1.289) 389 (84.6%) 332 (92.2%) co : 0.001 0.460 (0.293 ~ 0.721)
GA 47 (15.7%) 16 (7.4%) do : 0.999 0.000 (0.000 ~ NA) 21 (13.1%) 12 (8.4%) do : NA NA 63 (14.8%) 28 (7.8%) do : 0.999 0.000 (0.000 ~ NA)
AA 3 (1.0%) 0 (0.0%) re : 0.002 0.629 (0.468 ~ 0.847) 0 (0.0%) 0 (0.0%) re : 0.194 0.779 (0.534 ~ 1.135) 3 (0.7%) 0 (0.0%) re : 0.001 0.680 (0.540 ~ 0.856)
q. 0.088 0.037 0.001 0.626 (0.470 ~ 0.835) 0.070 0.040 0.209 0.791 (0.549 ~ 1.140) 0.080 0.039 0.001 0.680 (0.544 ~ 0.850)
HWE 0.573 0.600 0.443
−840 C > A
and -115G > A
GG 235 (78.3%) 195 (89.9%) co : <0.001 0.408 (0.246 ~ 0.675) 131 (81.88%) 129 (90.21%) co : 0.034 0.483 (0.246 ~ 0.948) 366 (79.6%) 324 (90.0%) co : <0.001 0.430 (0.288 ~ 0.642)
GA 61 (20.3%) 22 (10.1%) do : 0.999 0.000 (0.000 ~ NA) 28 (17.5%) 14 (9.79%) do : 1.000 0.000 (0.000 ~ NA) 89 (19.3%) 36 (10.0%) do : 0.999 0.000 (0.000 ~ NA)
AA 4 (1.3%) 0 (0.0%) re : 0.001 0.639 (0.493 ~ 0.829) 1 (0.63%) 0 (0.00%) re : 0.041 0.698 (0.495 ~ 0.985) 5 (1.1%) 0 (0.0%) re : <0.001 0.658 (0.535 ~ 0.808)
q. 0.115 0.051 <0.001 0.642 (0.501 ~ 0.823) 0.090 0.050 0.038 0.706 (0.508 ~ 0.981) 0.108 0.050 <0.001 0.661 (0.542 ~ 0.805)
HWE 0.432 0.538 0.318
Each P value was calculated with co-dominant (co), dominant (do) and recessive (re) models. Logistic regression analysis was applied to control for age and sex as covariables. Each q row’s P value was analyzed by the
Chi square test. Two genetic polymorphisms of the NR1H3 gene, −840 C > A and −115 G > A, were in complete linkage disequilibrium. CI, confidence interval; HWE, Hardy–Weinberg equilibrium; NA, not applicable;
OR, odds ratio; q., minor allele frequency.
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(P = 0.034 for the co-dominant model, P = 0.041 for the
recessive model). Moreover, in combined samples, the
minor allele of the −1830 T > C and −115 G >A polymor-
phisms were significantly more frequent in the SLE than
in the NC (P = <0.001 for the co-dominant model,
P = <0.001 for the recessive model). Although there was
no difference in the −1003 G > A polymorphism in re-
plication samples, the minor allele of the −1003 G >A
polymorphism was significantly more frequent in the
combined SLE patients than in the combined NC
(P = 0.001 for the co-dominant model, P = 0.001 for the
recessive model).
Linkage disequilibrium between SNPs and locus by
locus was examined. Two genetic polymorphisms of the
NR1H3 gene, −840 C >A and −115 G >A, were in
complete linkage disequilibrium. Therefore, −840 C >A
was excluded in the haplotype analysis. Three common
haplotypes for four polymorphisms were constructed
using the Haploview software: HT1 [TTGG], HT2
[CTGG] and HT3 [TCAA]. There was a significant dif-
ference between SLE and NC in the observed haplotype
HT1 [TTGG] (P = 0.033 for the co-dominant model,
P = 0.012 for the recessive model) and HT3 [TCAA]
(P = 0.008 for the co-dominant model, P = 0.009 for the
dominant model) (Table 2).
Associations between SLE phenotype and SNPs
The clinical characteristics according to genotype and
haplotype of NR1H3 gene are summarized in Table 3. In
the −1830 T > C polymorphism, arthritis was significantly
more common in the SLE patients with the −1830 C
allele (P = 0.005). Also, arthritis (P = 0.006), anti-dsDNATable 2 The haplotype frequencies of NR1H3 gene
Haplotype SLE
(n = 300) (n
HT1 +/+ 109 (36.3%) 103
[TTGG] +/− 169 (56.3%) 99
−/− 22 (7.3%) 15
HT2 +/+ 16 (5.3%) 15
[CTGG] +/− 111 (37.0%) 87
−/− 173 (57.7%) 115
HT3 +/+ 2 (0.7%) 0
[TCGG] +/− 30 (10.0%) 9
−/− 268 (89.3%) 208
HT others +/+ 3 (1.0%) 0
+/− 30 (10.0%) 3
−/− 267 (89.0%) 214
Haplotypes (HT) were analyzed using Haploview version 4.1 based on the EM algor
recessive(re) models. Logistic regression analysis was applied to control for age and
C > A and −115 G > A, were in complete linkage disequilibrium. Therefore, −840 C >
applicable; OR, odds ratio.(P = 0.041) and triglyceride (P = 0.011) were more com-
mon in the SLE patients with the −1003 A allele than
the −1003 G allele, but oral ulcer (P = 0.039) and central
nervous system (CNS) involvement (P = 0.015) were less
common in the −1003 A allele. In addition, arthritis
(P <0.001) was more common in the SLE patients with
the −115 A allele than −115 C allele, but oral ulcer
(P = 0.024) was less common in the −115 A allele
(Additional file 2).
The frequency of arthritis was significantly lower in pa-
tients who had haplotype HT1 [TTGG] (recessive model,
P = 0.004); however, arthritis was more common in pa-
tients with HT3 [TCGG] (dominant model, P = 0.003).
The frequency of lymphopenia was significantly lower in
patients who had haplotype HT2 [CTGG] (recessive
model, P = 0.027) (Additional file 3).
Transcriptional activity of the NR1H3 gene according to
the SNPs
To determine if the NR1H3 -1830 T > C, −1003 G > A
and −115 G > A polymorphisms are associated with al-
tered promoter activity, six reporter structures com-
posed of the promoter sequence carrying each allele and
the luciferase reporter gene were transfected into the
Hep3B cell line. The luciferase activity of the structure
containing −1830 C was less enhanced when compared
to that of the structure containing −1830 T (P = 0.009)
(Figure 1A). The trend of enhanced promoter activity of
the −1830 T structure is shown in different cell lines of
the COS-7 cells (P = 0.052) (Figure 1B). The luciferase
activity of the structure containing −1003 A was less
enhanced when compared to that of the structure con-
taining −1003 G (P = 0.030) (Figure 1A). The trend ofNC SLE versus NC
= 217) P value OR (95% CI)
(47.5%) co : 0.033 0.727 (0.542 ~ 0.974)
(45.6%) do : 0.808 0.956 (0.681 ~ 1.349)
(6.9%) re : 0.012 0.796 (0.666 ~ 0.951)
(6.9%) co : 0.255 0.847 (0.636 ~ 1.128)
(40.1%) do : 0.280 0.908 (0.761 ~ 1.082)
(53.0%) re : 0.507 0.884 (0.614 ~ 1.273)
(0.0%) co : 0.008 2.739 (1.304 ~ 5.751)
(4.1%) do : 0.009 1.662 (1.134 ~ 2.435)
(95.9%) re : 0.999 36085.247 (0.000 ~ NA)
(0.0%) co : <0.001 8.375 (2.557 ~ 27.431)
(1.4%) do : <0.001 2.984 (1.641 ~ 5.427)
(98.6%) re : 0.999 32475.263 (0.000 ~ NA)
ithm. Each P value was calculated with co-dominant(co), dominant(do), and
sex as covariables. Two genetic polymorphisms of the NR1H3 gene, −840
A was excluded in the haplotype analysis. CI, confidence interval; NA, not
Table 3 Comparison of the clinical characteristics according to the genotype and haplotype of NR1H3 gene in SLE
Characteristics −1830 T > C −1003G > A −115G > A
TT CT,CC P GG GA,AA P GG GA,AA P
n = 238 (79.3%) n = 62 (20.7%) value n = 250 (83.3%) n = 50 (6.7%) value n = 235 (78.3%) n = 65 (21.7%) value
Oral ulcera 122 (51.3%) 26 (41.9%) 0.191 130 (52.0%) 18 (36.0%) 0.039 124 (52.8%) 24 (36.9%) 0.024
Arthritisa 151 (63.4%) 51 (82.3%) 0.005 160 (64.0%) 42 (84.0%) 0.006 146 (62.1%) 56 (86.2%) <0.001
Anti-ds DNAa 156 (65.5%) 47 (75.8%) 0.124 163 (65.2%) 40 (80.0%) 0.041 153 (65.1%) 50 (76.9%) 0.071
CNS involvementa 19 (8.0%) 3 (4.8%) 0.295 22 (8.8%) 0 (0.0%) 0.015 20 (8.5%) 2 (3.1%) 0.106
Triglycerideb 97.8 ± 64.1 112.8 ± 67.1 0.108 95.6 ± 61.5 126.9 ± 74.9 0.007 95.3 ± 62.1 120.9 ± 71.2 0.011
Characteristics HT1 [TTGG] HT2 [CTGG] HT3 [TCGG]
+/+ +/−, −/− P +/+ +/−, −/− P +/+, +/− −/− P
n = 63 (41.7%) n = 88 (58.3%) value n = 24 (15.9%) n = 127 (84.1%) value n = 30 (19.8%) n = 121 (80.1%) value
Arthritisa 62 (56.9%) 140 (73.3%) 0.004 9 (56.3%) 193 (68.0%) 0.331 29 (90.6%) 173 (64.6%) 0.003
Leukopeniaa 61 (56.0%) 112 (58.6%) 0.652 11 (68.8%) 162 (57.0%) 0.356 20 (62.5%) 153 (57.1%) 0.558
Lymphopeniaa 100 (91.7%) 172 (90.1%) 0.628 12 (75.0%) 260 (91.5%) 0.027 30 (93.8%) 242 (90.3%) 0.526
aThis value is presented as the number of patients positive for the feature or antibody. bThis value was presented as the means ± SD. Leukopenia is defined as a
leukocyte count that is less than 4 × 103 cells/μL. Lymphopenia is defined as the lymphocyte count that is less than 1 × 103 cells/μL. Logistic regression analysis
was applied to control for age and sex as covariables. No association with SLE phenotypes was observed when the other SNPs were evaluated. No association
with SLE phenotypes was observed when the other haplotypes were evaluated. HT, haplotype; SLE, systemic lupus erythematosus; SNP, single nucleotide
polymorphism.
Figure 1 Functional effect of the polymorphisms on transcriptional activity. (A, B) Relative luciferase production (ratio of luciferase
production driven by the reporter construct to that by the promoter-less control vector, pGL3-Basic) in Hep3B cells (A) and COS-7 cells (B).
(C, D) Relative luciferase production by stimulation with 200 ng/mL LPS, 3 μmol/L GW3965 and 5 μmol/L T0901317 in Hep3B cells (C) and COS-7
cells (D). The P value was determined by a paired t test. *P <0.05. LPS, lipopolysaccharide.
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ture is shown in different cell lines of the COS-7 cells
(P = 0.061) (Figure 1B). There were no significant dif-
ferences between −115 G and −115 A in the observed
luciferase activity (Figure 1A, B).
Pharmacological treatment and reporter gene assay
NR1H3 transcriptional activity according to the stimu-
lants (LPS and synthetic ligands, such as GW3965 and
T0901317) was analyzed in Hep3B cells and COS-7 cells.
The luciferase activity of −1830 C was less enhanced
when compared to that of −1830 T in GW3965 and
T0901317 treated Hep3B cells (P = 0.034 and P <0.001,
respectively) (Figure 1C). The reduced enhancement of
transcriptional activity of the −1830 C structure was
reconfirmed in LPS- and T0901317-treated COS-7 cells
(P = 0.023 and P = 0.006, respectively) (Figure 1D). The
luciferase activity of −1003 A was less enhanced when
compared to that of −1003 G in GW3965- and
T0901317-treated Hep3B cells (P = 0.038 and P = 0.004,
respectively) (Figure 1C). Less enhanced transcriptional
activity of the −1003 A structure was replicated in
GW3965- and T0901317-treated COS-7 cells (P = 0.029
and P = 0.009, respectively) (Figure 1D). However, thereFigure 2 Results of an EMSA for the −1830 T > C polymorphism using
sequences of oligonucleotides used as probes and competitors. (B) Differenti
the transcription factor binding to 1830 T > C probe using competitive bindinwere no significant differences between −115 G and −115
A in the observed luciferase activity in Hep3B cells and
COS-7 cells treated with LPS, GW3965 and T0901317
(Figure 1C, D).
Nuclear extract preparation and electrophoretic mobility
shift assay
EMSA using nuclear extracts prepared from Hep3B cells
revealed a specific band with the −1830 T probe, but not
with the −1830 C probe. The shifted band produced by
the −1830 T probe was not visible in the presence of the
nonlabeled −1830 T probe but remained visible in the
presence of the nonlabeled −1830 C probe (Figure 2A). A
survey of a database of transcription factors suggested that
the −1830 T > C polymorphism generated a potential
GATA-3 binding motif. To clarify the involvement of
GATA-3, we performed a competition assay using GATA-
3 and CdxA probes, and found that the shifted band
corresponding to the −1830 T probe was completely com-
peted for by the unlabeled GATA-3 probe, but not by the
unlabeled CdxA probes (Figure 2B). The −1830 T specific
band was also competed by anti-GATA-3 antibodies
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) but not
supershifted (Figure 2C).nuclear extracts obtained from Hep3B cells. (A) Nucleotide
al binding of a nuclear protein to −1830 T > C alleles. (C) Identification of
g assay. EMSA, electrophoretic mobility shift assay.
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B cell lines were screened to measure mRNA expression
of NR1H3 gene according to the genotypes using RT-PCR.
As illustrated in Figure 3A, the −1830 TC type B cells
displayed a lower NR1H3 mRNA expression level than
the −1830 TT type B cells in SLE. Also, the −1830 TC
type B cells displayed a lower NR1H3 mRNA expression
level than the −1830 TT type B cells in NC. Moreover, the
NR1H3 expression level was significantly different bet-
ween genotypes in real-time PCR. The −1830 TC type
had an approximately 1.8-fold decrease compared to
the −1830 TT type in SLE. Also, the −1830 TC type had an
approximately 1.8-fold decrease compared to the −1830
TT type in NC (P = 0.03 and P = 0.025, respectively)
(Figure 3B).
Effect of LXR agonists on B cell proliferation according to
the genotypes
B cell proliferation assay was performed to determine
the effect of −1830 T > C polymorphism. ProliferationFigure 3 Effect of the −1830 T > C polymorphism on NR1H3 mRNA ex
separated by electrophoresis on 1% agarose gel and stained with EtBr. Gel
were determined by quantitative-PCR normalized to β-actin mRNA express
and the results are expressed as mean ± SD for three independent experim
of the −1830 T > C polymorphism on the NR1H3 gene on the B cells prolife
compound. When the tetrazolium is reduced, it produces a colored formazan
at 490 nm. Assays were conducted in triplicate, and the experiments were rep
the −1830 T > C polymorphism on the NR1H3 gene on B cells proliferation by
T0901317. Values are mean ± SD. The P value was determined by a paired t teof −1830 TC type was increased compared to that
of −1830 TT type in B cells from SLE patients (P = 0.011)
(Figure 3C). Proliferation of the −1830 TC type was in-
creased when compared to that of the −1830 TT type in
GW3965- and T0901317-treated B cells from SLE patients
(P = 0.040 and P = 0.017, respectively) (Figure 3D).
Discussion
In the present study, we evaluated the associations of gen-
etic polymorphisms of the NR1H3 and NR1H2 with SLE
in a Korean population. There were five genetic poly-
morphisms of the NR1H3 gene at −1851 T > C, −1830
T > C, −1003 G >A, −840 C > A and −115 G > A including
one novel SNP (−1003 G > A) between the promoter re-
gion and the second intron region. Also, we found that
the rare alleles of the −1830 T > C, −1003 G >A and −115
G >A polymorphisms were associated with a significantly
higher disease susceptibility. In the haplotype analysis,
there was a significant difference between SLE and NC in
the observed haplotype HT1 [TTGG] and HT3 [TCAA].pression and B cells proliferation assay. (A) RT PCR products were
s were examined by ultraviolet illumination. (B) The mRNA levels
ion. Each experiment was conducted in duplicate for each sample,
ents. The P value was determined by a paired t test. (C) The effect
ration assay. This is a colorimetric assay containing a tetrazolium
product that is soluble in cell culture medium and maximally absorbed
eated at least three times. Values are mean ± SD; *P <0.05. (D) Effect of
stimulation with 200 ng/mL LPS, 3 μmol/L GW3965 and 5 μmol/L
st. *P <0.05. LPS, lipopolysaccharide; SD, standard deviation.
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important role in the development of SLE.
Some genetic association studies of LXR genes have
been reported in different ethnic populations and dis-
eases, such as obesity [19], metabolic syndrome [20],
type 2 diabetes [21-23], Alzheimer’s disease [24,25], in-
flammatory bowel disease [26] and gallstone disease
[27]. Most studies have focused on the NR1H2 gene and
most studies have suggested that the LXR gene polymor-
phisms are associated with susceptibility and outcome of
metabolic diseases.
To investigate the effects of polymorphisms on NR1H3
expression, we used a functional assay of promoter activity
in reporter structures that contained mutant type or poly-
morphic promoters in the Hep3B cell line and COS-7 cell
line. Since the Hep3B cell line originates from human he-
patocellular carcinoma and LXR is synthesized in the liver,
spleen, kidney and macrophages, it was an appropriate cell
line for this study. To replicate the Hep3B cell line results,
we also tested the promoter activity in the COS-7 cell line
from African green monkey kidney [21]. Additionally, the
NR1H3 transcriptional activity according to the stimulants
(LPS, GW3965 and T0901317) was analyzed in Hep3B
cells and COS-7 cells.
The promoter reporter structure carrying the −1830 C
and −1003 A alleles displayed lower promoter activity than
the structure carrying the −1830 T and −1003 G alleles in
Hep3B cells and COS-7 cells. Moreover, the luciferase ac-
tivity of the structure containing −1830 C and −1003 A
was less enhanced when compared to that of the structure
containing −1830 T and −1003 G in GW3965- and
T0901317-treated cells.
The −1830 C allele, which is associated with arthritis,
displayed significantly lower promoter activity. The −1003
A allele, which has been linked with oral ulcer, arthritis,
anti-dsDNA, CNS involvement and triglyceride, displayed
significantly lower promoter activity. These findings sug-
gest that LXR regulates inflammatory signaling in SLE pa-
tients. It may be possible that under-expressed NR1H3
leads to autoantibodies production which is against joints
and DNA in SLE patients. Besides, the inflammation may
increase levels of triglycerides which is a risk factor for
atherosclerosis in lupus patients.
The frequency of arthritis was significantly lower in
patients who had haplotype HT1 [TTGG]; however,
arthritis was more common in patients with HT3
[TCGG]. The frequency of lymphopenia was signifi-
cantly lower in patients who had haplotype HT2
[CTGG]. These findings suggest that the disease pheno-
type is more common in patients with SLE who have
minor allele −1830 T > C, −1003 G > A and −115 G > A
polymorphisms than in those who have the major
homozygous genotype. These phenotype results were
consistent with the genotype results.In particular, the −1830 T > C promoter polymorphism
was significantly different in genotype analysis and clinical
manifestations. The −1830 T > C polymorphisms were lo-
cated in the promoter site, which is important for gene ex-
pression. Therefore, we focused on the functional effects
of −1830 T > C polymorphism. To determine if the genetic
variants created a transcription factor binding site, se-
quences were submitted to the TFSEARCH online pro-
gram, which revealed that the −1830 T > C polymorphism
might be a potential GATA-3 binding motif. GATA-3
belongs to the GATA family of transcription factors [28].
The GATA-3 transcription factor is a GATA binding
protein 3 that plays a crucial role in Th1 and Th2 develop-
ment. Some evidence suggests that the GATA-3 transcrip-
tion factor is correlated with lupus disease activity [29,30].
We performed an EMSA with nuclear extracts from
Hep3B cells using double-stranded oligonucleotide probes
that corresponded to the −1830 T > C. This polymorphism
affected a transcription factor binding in the promoter re-
gion of NR1H3 because a shifted band was found in the
presence of the −1830 T probe in the EMSA results. The
transcription factor bound to the −1830 T probe was
identified as GATA-3 through a competition assay, be-
cause GATA-3 was bound to the −1830 T allele promoter
with a higher affinity compared with that of the 1830 C
allele promoter. We also performed supershift assays
using a commercially available anti-GATA-3 antibody
and found that the anti-GATA-3 antibody could affect
DNA-protein complex formation in the −1830 T probe.
The −1830 T specific band was also competed by anti-
GATA-3 antibody. Our data suggest that, in the transcrip-
tion regulation of NR1H3 gene, GATA-3 might act as a
positive regulator because the −1830 T allele containing
the reporter construct showed higher promoter activity
than the −1830 C allele containing the reporter construct.
The results of the present study indicate that the binding
affinity of GATA-3 may be decreased in SLE patients who
carry the −1830 C allele.
The B cell proliferation assay was performed to deter-
mine the effect of −1830 T > C polymorphism. Prolifera-
tion of −1830 TC type was increased when compared to
that of −1830 TT type in basal, GW3965- and T0901317-
treated B cells from SLE patients. Also, proliferation of
the −1830 TC type was increased when compared to
the −1830 TT type in T0901317-treated B cells from NC.
LXR agonist treated cells proliferated less than untreated
cells. These findings are consistent with the results of pre-
vious studies that have shown that LXR agonist suppresses
cell proliferation [31,32].
Moreover, −1830 TC type B cells displayed a lower
NR1H3 mRNA expression level than the −1830 TT type B
cells in SLE. Also, the −1830 TC type B cells displayed a
lower NR1H3 mRNA expression level than the −1830 TT
type B cells in NC. These mRNA expression and
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liferation of B cells from SLE patients.
In our luciferase assay and proliferation assay, LXR was
activated by both T0901317 and GW3965 that has a simi-
lar tendency but the T0901317 effect was stronger than
that of GW3965. These findings are consistent with the re-
sults of previous studies that have shown that activation of
PXR targets may explain why T0901317 induces dramatic
liver steatosis, while GW3965 has a milder effect [33].
Conclusions
These results suggest that the NR1H3 gene genetic poly-
morphisms may be associated with disease susceptibility
and clinical manifestations of SLE. Especially, the −1830
T > C polymorphism within the NR1H3 promoter region
may be involved in regulation of NR1H3 expression.
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